KN
Therapeutic Areas
Zeria Pharmaceutical Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Neuzym | Digestive enzyme supplement (Dyspepsia) | Approved/Commercial |
| Pentasa (Mesalazine) | Ulcerative Colitis | Approved/Commercial |
| Kikyou Extract | Atopic Dermatitis | Phase 3 |
| TRK-820 (Nalfurafine) | Uremic Pruritus | Approved/Commercial |
| TW-001 | Functional Dyspepsia | Phase 3 |
| CBP-307 | Ulcerative Colitis, Crohn's Disease | Phase 2 |
| Colac / New Laxoberon | Constipation | Approved/Commercial |
| Aminoleban | Liver support / Enteral nutrition | Approved/Commercial |
Leadership Team at Zeria Pharmaceutical
YM
Yuji Morita
Representative Director and President (CEO)
SO
Shigeru Okuyama
Representative Director and Senior Managing Executive Officer
HY
Hiroshi Yamaguchi
Managing Executive Officer
TK
Takeshi Kondo
Managing Executive Officer
YO
Yoshihiko Oka
Managing Executive Officer
KI
Kunihiko Ito
Managing Executive Officer
YS
Yoshihisa Suzuki
Managing Executive Officer
KY
Kazunori Yoda
Managing Executive Officer